Solving Operational Complexity in ADC Oncology Trials: From Design to Execution

Antibody–drug conjugates (ADCs) are rapidly transitioning from scientific innovation to a central pillar of oncology drug development. By combining targeted antibodies with highly potent cytotoxic agents, ADCs enable a more precise approach to treating cancer and are being explored across an expanding range of tumor types.

As pipelines accelerate, many sponsors encounter a consistent challenge: these studies introduce a level of operational complexity that goes well beyond traditional oncology trials.

This complexity is not incidental. The specific payload and linker characteristics of each ADC shape its safety profile, pharmacokinetics, and therapeutic window—directly influencing both trial design and how studies must be executed.

While ADC trials retain familiar elements—oncology sites, response assessments, and safety oversight—the execution demands are significantly higher. Visit schedules are denser, safety monitoring is more specialized, and data collection spans a broader range of assessments and vendors.

Without deliberate planning, this complexity can increase site burden, delay timelines, and introduce variability in both data quality and trial conduct.

1. Elevated Site and Patient Burden

The challenge
ADC protocols typically involve more frequent visits, narrower visit windows, and a greater number of specialty assessments than conventional oncology trials. This places sustained pressure on both patients and sites.

Operationally, this increases the risk of missed visit windows, protocol deviations, and declining site performance over time—particularly when study assumptions are based on less complex oncology designs.

Considerations for execution
Feasibility should function as a stress test of real-world execution. Evaluating visit schedules, assessment sequencing, and contingency planning early helps identify operational pressure points.

Aligning monitoring intensity and site support with the true demands of the protocol is critical.

On the patient side, support strategies such as concierge services and proactive scheduling coordination can help maintain adherence throughout the study.

2. Patient Selection and Eligibility Complexity

The challenge
ADC trials often require tight alignment between biomarker status, prior lines of therapy, and organ function requirements. Eligibility criteria may include target expression thresholds (e.g., HER2-low, Trop-2), restrictions on prior therapies (including prior ADC exposure), and stricter hepatic, pulmonary, or hematologic parameters driven by payload-related toxicities.

These constraints can significantly increase screen failure rates and place additional burden on sites during screening.

Considerations for execution
Feasibility assessments should account for real-world patient availability within these constraints. Early engagement with sites to validate patient populations—combined with clear guidance on eligibility interpretation—can help reduce screen failures and avoid delays during enrollment.

3. Site Readiness for Mechanism-Specific Toxicities

The challenge
ADC therapies introduce safety profiles that are often less familiar and mechanism-specific compared to traditional oncology agents. Adverse events such as ocular toxicities and interstitial lung disease (ILD)/pneumonitis require early recognition and proactive management.

Variability in site experience can lead to inconsistent identification, delayed intervention, and uneven application of dose modification guidelines.

Considerations for execution
Site readiness must extend beyond enrollment capability. Sponsors should assess whether sites are equipped to recognize and manage ADC-related toxicities in real time.

Targeted training—focused on practical identification, grading, and management of key adverse events—can improve consistency. In some cases, management may require specialist input or adjudication processes (e.g., ophthalmologic or pulmonary review), introducing additional coordination requirements.

Clear escalation pathways and accessible medical support further ensure that emerging issues are addressed promptly. In ADC trials, site selection is as much about clinical readiness as it is about recruitment potential.

4. Expanded Data and Monitoring Complexity

The challenge
ADC trials generate substantially more—and more complex—data than traditional oncology studies. Expanded CRFs capture detailed safety signals, pharmacokinetics, immunogenicity, biomarkers, and dose modifications.

This complexity is amplified by ADC pharmacokinetics, which often involve multiple analytes (e.g., total antibody, conjugated drug, and free payload) and tightly controlled sampling windows. These requirements increase coordination demands at the site level.

At the same time, monitoring expectations increase, with greater focus on safety-critical and specialized data (e.g., ocular, PK/ADA).

Together, these factors place significant strain on sites, CRAs, and data management teams, increasing the risk of delayed entry, higher query volumes, and inconsistent data quality.

Considerations for execution
Effective CRF design starts with prioritization—distinguishing critical data from supportive endpoints. Risk-based monitoring approaches should be adapted to focus on high-impact data.

Deploying experienced CRAs and aligning monitoring strategies with ADC-specific risks helps maintain quality without overwhelming sites.

5. Real-Time Safety Signal Detection and Response

The challenge
ADC trials compress the timeline between data generation and clinical decision-making. Emerging safety signals may require rapid action—dose modifications, treatment interruptions, or protocol-defined interventions based on specific toxicity thresholds.

Delays or inconsistencies in interpreting and acting on these signals can introduce patient risk, protocol deviations, and variability across sites.

Considerations for execution
Effective safety management depends on tight alignment between clinical, safety, and operational teams. Near real-time data visibility, structured communication pathways, and predefined decision frameworks enable faster, more consistent responses.

In this environment, organizational integration becomes a meaningful advantage. When clinical operations, safety, and data management function as a coordinated unit—rather than across fragmented vendors—teams can reduce lag between data review and decision-making and respond more consistently to emerging risks.

6. Operational Complexity of Dynamic Dosing

The challenge
Frequent dose modifications are a defining feature of many ADC trials. Dose reductions, interruptions, and holds—while clinically necessary—introduce complexity across scheduling, data capture, safety reporting, and supply management.

Without clear processes, dosing variability can drive protocol deviations and inconsistent documentation.

Considerations for execution
Dose modification strategies must be translated into clear, operational guidance for sites. Providing practical decision frameworks supports consistent implementation.

Inconsistent implementation or documentation of dose modifications can also affect downstream data interpretation, including exposure–response analyses and efficacy endpoints.

Close coordination across clinical, safety, data, and supply functions is essential to ensure that dose changes are executed smoothly and accurately reflected across systems.

7. Vendor Coordination and Timeline Control

The challenge
ADC trials require coordination across a broad ecosystem of specialized vendors, including central laboratories, bioanalytical labs (PK/ADA), imaging providers, ophthalmologic assessments, and digital health platforms.

Each vendor introduces distinct startup requirements, timelines, and dependencies. As complexity increases, so does the risk that parallel activities become sequential—delaying site activation and downstream milestones.

Considerations for execution
Vendor coordination is a primary driver of timeline performance in ADC trials. Strong project management ensures alignment across startup activities, clear ownership of deliverables, and consistent communication across vendors.

Actively managing interdependencies and maintaining momentum across workstreams is essential to keeping studies on track from startup through execution.

8. Continuous Data Integration and Reconciliation

The challenge
ADC trials generate multiple parallel data streams—from PK/PD, immunogenicity, central labs, and specialty assessments—that must be aligned to support safety monitoring and development decisions.

Delayed or fragmented reconciliation increases query volume, creates downstream pressure, and can impact timelines and regulatory readiness.

Considerations for execution
Leading teams treat reconciliation as a continuous process rather than a back-end activity. Mapping data dependencies early and prioritizing safety- and dosing-critical data ensures that effort is focused where timing and accuracy matter most.

Embedding reconciliation into routine data review helps prevent issues from accumulating and supports more reliable, decision-ready data throughout the study.

At the site level, ADC handling and preparation may also require specialized pharmacy procedures and cytotoxic safety precautions—introducing additional operational considerations that must be planned for in advance.

Conclusion: Designing for Execution in ADC Trials

ADCs represent a significant advancement in oncology—but they also redefine the operational demands of clinical trials.

Their complexity spans site execution, patient selection, safety management, data oversight, and vendor coordination, creating an environment where small misalignments can have amplified downstream effects. These demands are not incremental—they require fundamentally different approaches to trial design, site engagement, and real-time execution.

For sponsors, the implication is clear: execution strategies must be intentionally designed for ADC trials from the outset.

Organizations that align operational models, invest in site readiness, and ensure integration across clinical, safety, and data functions are better positioned to:

• Maintain timelines
• Protect data quality
• Support consistent, high-quality trial conduct

As ADC development continues to accelerate, organizations that can translate complexity into consistent, high-quality execution will be best positioned to deliver reliable data, protect patient safety, and bring these therapies to patients faster.